Q-omics provides the consensus-scored HEATR5B profile across patient tissues and cancer cell-line models. HEATR5B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HEATR5B is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, HEATR5B protein abundance shows 33,747 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where HEATR5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEATR5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEATR5B survival associations across molecular data types. HEATR5B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEATR5B RNA expression–survival associations across cancer types. High HEATR5B expression shows unfavorable associations in ACC, KICH and KIRP, but favorable associations in KIRC, SCLC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HEATR5B RNA expression.
This table summarizes HEATR5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HEATR5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEATR5B shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, KIRC, CHOL and LIHC. The BLCA box plot shows higher HEATR5B RNA expression in tumor versus normal tissue (log2 FC = +0.532, t-test p < 0.001).
This table shows molecular features associated with HEATR5B in patient tissues and cancer cell lines. In patient samples, HEATR5B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HEATR5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
